Kadmon Pharmaceuticals Partners with Oncology Pharmacy for New Chronic Graft-Versus-Host Disease Therapy
Kadmon Pharmaceuticals selects Onco360 to be a specialty pharmacy partner for Rezurock (belumosudil).
Kadmon Pharmaceuticals announced in a July 21, 2021 press release the selection of Onco360, an independent Oncology Pharmacy, to be a specialty pharmacy partner for Rezurock (belumosudil). Rezurock is a new oral treatment for the treatment of chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy for adult and pediatric patients 12 years and older.
FDA approved Rezurock on July 16, 2021, which is distributed and marketed by Kadmon Pharmaceuticals, following the Phase II KD025-213 clinical trial (NCT03640481).
Chronic GVHD is the leading cause of non-relapse mortality following allogeneic HCT and often develops within the first year after allogeneic HCT, according to the National Comprehensive Cancer Network (NCCN) Guidelines for Hematopoietic Cell Transplantation (HCT). It also can affect multiple organ systems, including skin, gastrointestinal tract, liver, lungs, and more.
First-line treatment for chronic GVHD involves systemic corticosteroids. But according to the NCCN guidelines, patients may develop steroid-refractory disease and require additional/alternative treatment.
Source: BusinessWire, Kadmon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
